Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer

Han, Shuwen; Yangyanqiu, Wang; Chu, Jian; Boyang, Hu; Chen, Gong; Jing, Zhuang

doi:10.1016/j.tranon.2022.101598

Cited by 14 publications

(14 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47 It has also been found that butyric acid can enhance the efficacy of oxaliplatin by regulating the function of CD8 + T cells in the tumor microenvironment. 48 Some studies have demonstrated the crucial role of butyric acid in promoting Th1 differentiation and maintaining intestinal immune homeostasis. 49 Th1 cells represent a distinct subset of T helper cells characterized by their production of cytokines, including IFN-γ and IL-2, which serve to activate and augment the functionality of cytotoxic CD8 + T lymphocytes (CD8 + CTLs).…”

Section: Discussionmentioning

confidence: 99%

Ganoderma lucidum Polysaccharide Supplementation Significantly Activates T-Cell-Mediated Antitumor Immunity and Enhances Anti-PD-1 Immunotherapy Efficacy in Colorectal Cancer

Li,

Zhou,

et al. 2024

J. Agric. Food Chem.

View full text Add to dashboard Cite

Ganoderma lucidum polysaccharide (GLP) is a prebiotic with immunomodulatory effects. However, the therapeutic potential of GLP in tumor immunotherapy has not been fully explored, especially in T cell-mediated antitumor immunity. In this study, we found that GLP significantly inhibited tumor growth and activated antitumor immunity in colorectal cancer (CRC). In the spleens and tumor tissues, the proportion of cytotoxic CD8 + T cells and Th1 helper cells increased, while immunosuppressive Tregs decreased. Additionally, microbiota dysbiosis was alleviated by GLP, and short-chain fatty acid production was increased. Meanwhile, GLP decreased the ratio of kynurenine and tryptophan (Kyn/Trp) in the serum, which contributed to antitumor immunity of T cells. More importantly, the combination of GLP and the immune checkpoint inhibitor anti-PD-1 monoclonal antibody further enhanced the efficacy of anti-PD-1 immunotherapy. Thus, GLP as a prebiotic has the potential to be used in tumor immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Ganoderma lucidum Polysaccharide Supplementation Significantly Activates T-Cell-Mediated Antitumor Immunity and Enhances Anti-PD-1 Immunotherapy Efficacy in Colorectal Cancer

Li,

Zhou,

et al. 2024

J. Agric. Food Chem.

View full text Add to dashboard Cite

show abstract

“… 108 In accordance with this, treatment of the colorectal cancer cell line HCT116 with sodium butyrate also inhibited tumor cell growth in vitro and promoted epigenetic methylation reprogramming. 109 A recent study demonstrated a synergistic effect of butyrate with oxaliplatin in preventing proliferation, invasion and metastasis of CRC cells in vitro and in vivo . 109 A protective role for butyrate and the other two main SCFAs (propionate and acetate) was also reported in 5-FU-induced gastrointestinal mucositis by dampening excessive inflammation.…”

Section: Microbiota-derived Metabolites May Affect Pdac Development A...mentioning

confidence: 99%

“… 109 A recent study demonstrated a synergistic effect of butyrate with oxaliplatin in preventing proliferation, invasion and metastasis of CRC cells in vitro and in vivo . 109 A protective role for butyrate and the other two main SCFAs (propionate and acetate) was also reported in 5-FU-induced gastrointestinal mucositis by dampening excessive inflammation. 110 In PDAC patients, the relative abundance of butyrate-producing bacteria in the gut was found to be decreased 43 , 44 and lower concentrations of butyrate in fecal samples of PDAC patients were also reported.…”

Section: Microbiota-derived Metabolites May Affect Pdac Development A...mentioning

confidence: 99%

Roles of microbiota in pancreatic cancer development and treatment

Cruz,

Tintelnot,

Gagliani

2024

Gut Microbes

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis. This is due to the fact that most cases are only diagnosed at an advanced and palliative disease stage, and there is a high incidence of therapy resistance. Despite ongoing efforts, to date, the mechanisms underlying PDAC oncogenesis and its poor responses to treatment are still largely unclear. As the study of the microbiome in cancer progresses, growing evidence suggests that bacteria or fungi might be key players both in PDAC oncogenesis as well as in its resistance to chemo- and immunotherapy, for instance through modulation of the tumor microenvironment and reshaping of the host immune response. Here, we review how the microbiota exerts these effects directly or indirectly via microbial-derived metabolites. Finally, we further discuss the potential of modulating the microbiota composition as a therapy in PDAC.

show abstract

“…Clinical research found that after preoperative neoadjuvant radiochemotherapy, responder CRC patients show more enriched levels of butyrate-producing bacteria and SCFAs in the feces than those who did not (135). Butyrate can be used as the synergist of oxaliplatin to synergistically enhance the anti-cancer effect (136). Butyrate directly facilitated the chemotherapy efficacy of oxaliplatin by regulating CD8 + T cells.…”

Section: Targeting Microbiota-scfas Axis For Treatments Of Gastrointe...mentioning

confidence: 99%

Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy?

et al. 2023

View full text Add to dashboard Cite

Tumor immune microenvironment (TIME), a tumor-derived immune component, is proven to be closely related to the development, metastasis, and recurrence of tumors. Gut microbiota and its fermented-metabolites short-chain fatty acids (SCFAs) play a critical role in maintaining the immune homeostasis of gastrointestinal tumors. Consisting mainly of acetate, propionate, and butyrate, SCFAs can interact with G protein-coupled receptors 43 of T helper 1 cell or restrain histone deacetylases (HDACs) of cytotoxic T lymphocytes to exert immunotherapy effects. Studies have shed light on SCFAs can mediate the differentiation and function of regulatory T cells, as well as cytokine production in TIME. Additionally, SCFAs can alter epigenetic modification of CD8+ T cells by inhibiting HDACs to participate in the immune response process. In gastrointestinal tumors, the abundance of SCFAs and their producing bacteria is significantly reduced. Direct supplementation of dietary fiber and probiotics, or fecal microbiota transplantation to change the structure of gut microbiota can both increase the level of SCFAs and inhibit tumor development. The mechanism by which SCFAs modulate the progression of gastrointestinal tumors has been elucidated in this review, aiming to provide prospects for the development of novel immunotherapeutic strategies.

show abstract

Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer

Cited by 14 publications

References 46 publications

Ganoderma lucidum Polysaccharide Supplementation Significantly Activates T-Cell-Mediated Antitumor Immunity and Enhances Anti-PD-1 Immunotherapy Efficacy in Colorectal Cancer

Ganoderma lucidum Polysaccharide Supplementation Significantly Activates T-Cell-Mediated Antitumor Immunity and Enhances Anti-PD-1 Immunotherapy Efficacy in Colorectal Cancer

Roles of microbiota in pancreatic cancer development and treatment

Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy?

Contact Info

Product

Resources

About